CompletedPhase 3NCT01605136
Phase III Confirmatory Study in Erythropoietic Protoporphyria
Studying Autosomal erythropoietic protoporphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Clinuvel Pharmaceuticals Limited
- Principal Investigator
- Robert Desnick, MDMt. Sinai Medical Center
- Intervention
- Afamelanotide(drug)
- Enrollment
- 93 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2013
Study locations (7)
- University of Alabama, Birmingham, Alabama, United States
- University of California, San Francisco, San Francisco, California, United States
- Henry Ford Medical Center, Detroit, Michigan, United States
- Mt. Sinai, New York, New York, United States
- Carolina's Medical Center Cannon Research, Charlotte, North Carolina, United States
- University of Texas, Galveston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01605136 on ClinicalTrials.govOther trials for Autosomal erythropoietic protoporphyria
Additional recruiting or active studies for the same condition.
See all trials for Autosomal erythropoietic protoporphyria →